Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

74.71 -0.42 (-0.56%)

Streaming Delayed Price Updated: 3:43 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	994,076
Open	73.74
Bid (Size)	74.63 (100)
Ask (Size)	74.75 (200)
Prev. Close	75.13
Today's Range	73.35 - 75.13
52wk Range	23.95 - 86.74
Shares Outstanding	141,797,854
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...

Via MarketMinute

When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗

March 23, 2026

Ionis Pharmaceuticals and Waste Management insiders sell in early 2026, creating buying opportunities in their stocks while analysts raise price targets.

Via MarketBeat

Performance

YTD	-6.2%	-6.2%
1 Month	-8.8%	-8.8%
3 Month	-5.6%	-5.6%
6 Month	+13.5%	+13.5%
1 Year	+174.1%	+174.1%

More News

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

March 23, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Shows High Technical and Setup Ratings for Potential Breakout ↗

February 24, 2026

Via Chartmill

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup ↗

January 23, 2026

Via Chartmill

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

Via The Motley Fool

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

Via The Motley Fool

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

Via The Motley Fool

Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally

March 11, 2026

Via MarketMinute

Ionis announces changes to Board of Directors

March 09, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

February 27, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

February 26, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

February 25, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

February 19, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis updates time for fourth quarter and full year 2025 financial results webcast

February 17, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

Via Finterra

Ionis to hold fourth quarter and full year 2025 financial results webcast

February 11, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

February 04, 2026

From Biogen Inc.

Via GlobeNewswire

What a $20 Million Bet on a Stock Down 3% Signals for Investors ↗

February 03, 2026

Via The Motley Fool

Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million ↗

February 03, 2026

Via The Motley Fool

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

January 21, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

January 12, 2026

From Biogen Inc.

Via GlobeNewswire

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

January 12, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

January 07, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?

Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market

What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 74.71

When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 04/02/26 03:43 PM ET

What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 10.59B

How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?

Ionis Pharmaceuticals, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.